疣是由人乳头瘤病毒(HPV)引起的皮肤生长。 HPV 有 60 多种类型,其中一些容易引起皮肤疣。局部治疗可能会在几周内解决疣问题,并且副作用最小。局部治疗可能并不总是有效。因此,液氮冷冻疗法是一种合适的治疗选择,其治愈率为60%至90%,复发率低于20%至10%。
因此,新产品的开发预计将创造未来几年对疣治疗药物的巨大需求,预计这将进一步推动疣治疗市场的发展。
由于该地区 COVID-19 病例呈指数级增长,欧洲经济受到严重影响。西班牙、意大利、德国、法国和英国是受影响最严重的欧洲国家。欧洲各国在今年年初成功缓解疫情后,Covid-19 病例再次出现。实现可持续发展目标 (SDG) 和最近欧洲针对艾滋病毒、乙型肝炎 (HBV)、丙型肝炎 (HCV) 和性传播感染的指导检测至关重要。 COVID-19 需要卫生系统和公共卫生措施的快速调整,并对欧洲地区的艾滋病毒、病毒性肝炎和性传播感染检测产生了相当大的影响。根据 Eurosurveillance 的数据,初步结果显示,来自 34 个国家的 95% 的受访者表示,在 2020 年 3 月至 5 月期间,在 COVID-19 爆发的头几个月内,测试人数不到预期人数的一半。这种情况在 2020 年 6 月至 8 月期间一直持续到当大多数国家的措施不太严格时,程度较小。这些发现表明检测量下降。随着报告的 COVID-19 病例不断增加,许多国家重新实施限制,指导对于最大限度地减少检测中断并确保现有艾滋病毒、肝炎和性传播感染检测服务的长期可持续性至关重要。除此之外,大流行还导致包括皮肤科就诊在内的非紧急医疗就诊次数大幅减少。因此,COVID-19 对市场增长产生了负面影响。
欧洲的疣治疗市场预计将从2021年的5.381亿美元增长到2028年的6.676亿美元;预计 2021 年至 2028 年复合年增长率为 3.1%。技术进步正在塑造疣治疗方法,以克服现有治疗程序的缺点。 Swift System 是 Saorsa 开发的一项新技术,提供了一种治疗引起跖疣的病毒感染的方法。经过欧洲研究证实,FDA 于 2018 年批准了这项技术。研究表明,在超过 13,000 名接受 Swift 治疗的患者中,治疗消除疣的有效率为 85%,复发率低于 1%。它涉及通过表面接触探针将皮肤精确地暴露在预定深度的低水平微波能量下,产生免疫反应并利用人体的免疫系统来应对感染。此类创新可能会在未来几年为疣治疗市场带来新趋势。
从类型来看,寻常疣细分市场占据了2020年欧洲疣治疗市场的最大份额;从治疗方式来看,物理破坏细分市场占据了欧洲疣治疗市场的最大份额2020年市场。就最终用户而言,医院细分市场在2020年欧洲疣治疗市场中占据最大份额。
准备本疣治疗报告时提到的一些主要一手和二手来源欧洲市场包括公司网站、年度报告、财务报告、国家政府文件、统计数据库等。报告中列出的主要公司包括 Bausch Health Companies Inc.、Euro Vital Pharma GmbH、Cipla Inc.、Koninklijke Utermöhlen NV、Scholl\'s Wellness Company、Teva Pharmaceutical Industries Ltd、GlaxoSmithKline plc. 和 AIM ImmunoTech Inc.
按类型
通过治疗
由最终用户 span>
按国家/地区
< ul>
Strategic insights for Europe Warts Therapeuctis involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 538.1 Million |
Market Size by 2028 | US$ 667.6 Million |
Global CAGR (2021 - 2028) | 3.1% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By 类型
|
Regions and Countries Covered | 欧洲
|
Market leaders and key company profiles |
The regional scope of Europe Warts Therapeuctis refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Warts Therapeuctis Market is valued at US$ 538.1 Million in 2021, it is projected to reach US$ 667.6 Million by 2028.
As per our report Europe Warts Therapeuctis Market, the market size is valued at US$ 538.1 Million in 2021, projecting it to reach US$ 667.6 Million by 2028. This translates to a CAGR of approximately 3.1% during the forecast period.
The Europe Warts Therapeuctis Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Warts Therapeuctis Market report:
The Europe Warts Therapeuctis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Warts Therapeuctis Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Warts Therapeuctis Market value chain can benefit from the information contained in a comprehensive market report.